Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT04569058
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
9 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Transcranial Photobiomodulation — DEVICE
    Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.

Study Details

An open label trial to assess the safety and efficacy of transcranial photobiomodulation (tPBM) in improving autistic traits in ADHD youth.

Key Dates

Start date
Jan 14, 2021
Status verified
Oct 2025
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Transcranial Photobiomodulation
    Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.

Primary Outcome Measure

Change From Baseline in Attention Deficit Hyperactivity Disorder Symptom Checklist (ADHD-SCL) [ Time Frame: Baseline to week 8 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Boston, MA

By condition
ADHDAutism spectrum disorder
By specialty
PsychiatryMental healthBehavioral healthPediatrics
By research site
Massachusetts General Hospital· Boston, MA

Related Studies